<DOC>
	<DOCNO>NCT00683592</DOCNO>
	<brief_summary>This randomize , double-blind , placebo-controlled , multicenter , 8-week , clinical trial design assess efficacy safety vilazodone evaluate genetic biomarkers treatment response associate vilazodone use adult patient diagnose MDD DSM-IV-TR criterion .</brief_summary>
	<brief_title>Randomized , Double-Blind , Placebo Controlled Study Vilazodone 's Efficacy , Safety , Biomarkers Response Major Depressive Disorder ( MDD )</brief_title>
	<detailed_description>This randomize , double-blind , placebo-controlled , multicenter , 8-week , clinical trial design assess efficacy safety vilazodone evaluate genetic biomarkers treatment response associate vilazodone use adult patient diagnose MDD DSM-IV-TR criterion . This study enroll approximately 470 patient approximately 10 clinical site . Safety efficacy assess visit . A DNA sample collect analyzed response vilazodone .</detailed_description>
	<mesh_term>Disease</mesh_term>
	<mesh_term>Depressive Disorder</mesh_term>
	<mesh_term>Depression</mesh_term>
	<mesh_term>Depressive Disorder , Major</mesh_term>
	<mesh_term>Vilazodone Hydrochloride</mesh_term>
	<criteria>Patients 1870 year age . A diagnosis MDD , single episode recurrent , accord DSMIVTR ( 296.2/296.3 ) current Major Depressive Episode less two year 's duration minimum duration least 4 week . Meets DSMIVTR criterion Major Depressive Disorder . HAMD score ≥ 22 first 17 item 21item HAMD . HAMD item 1 ( depressed mood ) score ≥ 2 . Patients must able provide write informed consent Patients must able speak , read understand English Patients current ( within 6 month prior Screening Visit ) Axis I disorder Post Traumatic Stress Disorder , Eating Disorder , Obsessive Compulsive Disorder . Patients history schizophrenia , schizoaffective disorder bipolar I II disorder ( history hypomanic manic episode ) . Patients meet DSMIVTR criterion substance abuse ( alcohol drug ) within 3 month prior Screening Visit substance dependence within 6 month prior Screening Visit . Patients meet criterion follow DSMIVTR MDD Specifiers : [ ] With Catatonic Features ; [ b ] With Postpartum Onset ; [ c ] With Seasonal Pattern [ ] severe Psychotic Features . Patients receive formal psychotherapy psychotherapy within 12 week prior Screening Visit . Patients one follow : In month prior screening , active suicidal ideation intent act , without specific plan . In month prior screening , suicidal ideation specific plan intent . Have make suicide attempt within 6 month prior screen visit . In opinion Investigator , currently significant risk suicide . Patients inadequate response least 2 consecutive antidepressant different class give adequate dos adequate duration . Patients receive electroconvulsive therapy within 6 month prior Screening Visit . Patients currently take psychotropic drug . Patients take psychotropic drug must discontinue prior Screening Visit . The minimum discontinuation period outline study protocol . Patients take migraine medication serotonergic mechanism action Patients take CYP3A4 inhibitor grapefruit juice , ketoconazole , diltiazem , macrolide antibiotic montelukast Patients know hypersensitivity SSRIs ( selective serotonin reyptake inhibitor ) 5HT1a agonist . Patients previously treat vilazodone ( also know SB659746A EMD 68 843 ) . Patients history clinically significant cardiac , renal , neurologic , cerebrovascular , hepatic , hematologic , metabolic pulmonary disorder . Patients serious medical disorder condition would , investigator 's opinion , preclude administration study medication . Female patient must pregnant , lactate , plan become pregnant time study participation . All female patient must least 1 year post menopausal irreversibly surgically sterilize ( hysterectomy , oophorectomy , bilateral tubal ligation resection ) determine risk pregnancy . Patients clinically significant abnormality electrocardiogram . Patients clinically significant abnormal laboratory finding . Patients positive drug screen . Patients , opinion investigator , would noncompliant visit schedule study procedure . Patients take investigational drug participate investigational drug trial within past 30 day .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>October 2010</verification_date>
</DOC>